Apellis Valuation Ignores Empaveli Potential, Says Analyst

Core Viewpoint - Apellis Pharmaceuticals is experiencing significant growth potential in the rare kidney disease market, particularly with its newly approved treatment, Empaveli, which could enhance the company's revenue outlook in the coming years [1][6]. Early Commercial Performance - In Q3, Apellis reported U.S. net product revenue of $27 million for Empaveli, with 267 new patient start forms recorded since its late July approval, indicating approximately 5% penetration of the estimated 5,000 U.S. patient market [4]. - Management noted positive early payer traction, with no full coverage denials reported so far [4]. Competitive Positioning and Market Dynamics - Empaveli's broader label, including indications for IC-MPGN, pediatric, and post-transplant patients, is driving early uptake, with the company asserting stronger efficacy compared to Novartis AG's Fabhalta [5]. - Bank of America models peak U.S. sales of $508 million by 2033, assuming 20% peak penetration, which could add $10 per share to the price forecast of $28 [5]. Future Catalysts - The approval of the Syfovre prefilled syringe, expected to be filed in the first half of 2026, could accelerate growth in the geographic atrophy (GA) business, which has faced challenges due to the loss of charitable foundation funding [7][8]. - The prefilled syringe is viewed as a near-term competitive advantage that could expand market share and contribute to overall market growth, with potential impacts expected in 2027 [8]. Stock Performance - Apellis Pharmaceuticals shares increased by 2.37% to $21.52 at the time of publication [8].